Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME

This article was originally published in The Tan Sheet

Executive Summary

ZOVIRAX RESISTANCE NOT CLINICALLY SIGNIFICANT, BURROUGHS WELLCOME research scientist Jack Hill suggested at a May 19 FDA public hearing on the company's Rx-to-OTC switch application for Zovirax (acyclovir). "We believe that acyclovir-resistant viruses ...cause little if any clinically significant diseases in people with healthy immune systems," Hill said.

Topics

UsernamePublicRestriction

Register

PS082832

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel